ERBB2 and ductal breast carcinoma in situ: In addition, NOTCH3 can interact with HER2 to induce ductal carcinoma in situ, suggesting that combination therapy with anti-HER2 antibodies and Notch antagonists (such as GSIs) could be effective treatment for such lesions [44].